Identifying the Potential Diagnostic Gene Biomarkers and Forecasting the Potential Therapeutic Agents for Advanced Diabetic Nephropathy Based on Pyroptosis and Ferroptosis
Qin Dai,Siyi Huang,Yi Fang,Xiaoqiang Ding
DOI: https://doi.org/10.2147/jir.s467388
IF: 4.5
2024-09-01
Journal of Inflammation Research
Abstract:Qin Dai, 1, 2 Siyi Huang, 3 Yi Fang, 4 Xiaoqiang Ding 4 1 Department of Nephrology, Xuhui District Central Hospital, Shanghai, People's Republic of China; 2 Department of Nephrology, Zhongshan-Xuhui Hospital, Fudan University, Shanghai, People's Republic of China; 3 Department of Nephrology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People's Republic of China; 4 Department of Nephrology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China Correspondence: Yi Fang; Xiaoqiang Ding, Department of Nephrology, Zhongshan Hospital, Fudan University, Shanghai, 200032, People's Republic of China, Email ; Background: Diabetic nephropathy (DN) is a prevalent complication of diabetes, often leading to end-stage kidney disease (ESKD). Advanced DN progresses to ESKD rapidly, yet effective diagnostic indicators and treatments are lacking. Methods: Two DN-related datasets were obtained from the Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) were identified using the R packages. Pyroptosis-related genes (PRGs) and ferroptosis-related genes (FRGs) were collected from their respective database. Pyroptosis- and ferroptosis-related differentially expressed genes (PFRDEGs) were identified by overlapping DEGs, PRGs, and FRGs for further analysis, including functional enrichment and immune infiltration. Hub genes were identified using a PPI network via MCODE-plugin in Cytoscape. GeneMANIA was utilized to explore intermolecular interactions among hub genes. Based on these hub genes, a diagnostic model was constructed using the receiver operating characteristic curve and potential therapeutic agents were retrieved. Correlation analysis between hub genes and estimated glomerular filtration rate was performed using Nephroseq v5 database, and expression of hub genes was validated in external GEO database, Nephroseq v5 database and DN mice in vivo. Results: Four hub genes (CYBB, LCN2, JUN and ADIPOQ) were identified, and three of the four hub genes (CYBB, LCN2 and ADIPOQ) were found to be potential biomarkers for advanced DN. On this basis, three potential therapeutic agents were screened. More importantly, a series of biological experiments confirmed that CYBB and LCN2 were significantly up-regulated in DN mice. Conclusion: This study identifies three hub genes as diagnostic biomarkers and mines three potential therapeutic agents for advanced DN, providing new insights into the role of pyroptosis and ferroptosis in advanced DN and laying the foundation for future research. Keywords: diabetic nephropathy, pyroptosis, ferroptosis, bioinformatics, diagnostic biomarkers As an urgent challenge for public health, 1 diabetic nephropathy (DN), also known as diabetic kidney disease, is a significant chronic microvascular complication of diabetes mellitus. 2 Globally, DN is the leading cause of CKD [including end-stage kidney disease (ESKD)] and an important risk factor for cardiovascular disease and early death in diabetic patients. 3,4 DN can be categorized into two groups as early DN and advanced DN according to the levels of urinary albumin-to-creatinine ratio (UACR) and renal function, and advanced DN was defined as UACR > 300mg/g or estimated glomerular filtration rate (eGFR) < 90mL/min. 5 Compared with early DN, patients with advanced DN have a higher risk of declining renal function and progression to ESKD. 6 Nevertheless, there is currently a lack of effective diagnostic means and treatments for advanced DN. In terms of diagnostics, proteinuria and eGFR are nowadays crucial indicators for diagnosing DN, but they have their limitations. For example, among diabetic patients with massive proteinuria, approximately 70% of renal puncture biopsies confirm the presence of DN, 7,8 and only 40% of patients with type 2 diabetes and microalbuminuria exhibit the typical pathology of DN. 9 Furthermore, an increasing number of studies have discovered that diabetic patients with normal urinary albumin can still progress to DN, as evidenced by a decrease in eGFR to less than 60mL·min −1 (1.73 m 2 ) −1 and the presence of typical DN in renal puncture pathology. 8,10 Above all, there is the absence of effective measures to diagnostic advanced DN. In terms of treatment, although new drugs such as SGLT-2i, DPP-4 inhibitors, and finerenone have provided additional treatment options for DN, 11 many patients with DN still progress to ESKD due to the limited effectiveness of the aforementioned drugs. Consequently, in-depth research on the pathogenesis of DN for identifying effe -Abstract Truncated-
immunology